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1. Abstract 
 
Background: A former placebo-controlled trial demonstrated that administration of a 
L-cystine, medicinal yeast and pantothenic acid (CYP complex)-based dietary 
supplement improved anagen rates in women with telogen effluvium. 
 
Objective: To verify efficacy of CYP complex in women aged 60 years or more. 
 
Methods: A randomized, double-blind, placebo-controlled trial was conducted over 6 
months in 36 healthy women suffering from telogen effluvium. Anagen rates were 
determined with digitalized epiluminiscence microscopy and digital imaging 
performed before, after 3 and 6 months of treatment. 
 
Results: Both placebo and active compound showed significant improvement of 
mean anagen rates. Between the two groups these changes were statistically not 
significant. Inclusion of study patients in relation to seasonality of hair growth and 
shedding was inhomogeneous. 
 
Conclusions: Despite prior evidence of efficacy of CYP-based nutritional 
supplement over placebo, superiority of the active compound over placebo was not 
demonstrated in this study. This observation was explained by inhomogeneous 
inclusion of study patients in relation to seasonality of hair growth and shedding. 
Depending on periodicity of hair growth and shedding, heterogeneity of patient 
inclusion may be enough to distort clinical efficacy results. 
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2. Introduction 
 
Combining epiluminiscence microscopy with digital imaging has evolved as a simple 
to perform, noninvasive and reproducible method for the measurement of efficacy of 
hair growth promoting agents [1-4]. In a former double blind placebo-controlled study 
using the TrichoScan technique, a L-cystine, medicinal yeast and pantothenic acid 
(CYP complex)-based dietary supplement was demonstrated to positively influence 
hair growth in otherwise healthy women aged between 25 and 65 years complaining 
of hair loss, as opposed to placebo [5]. Since an open label pilot study with 5 women 
aged between 64 and 84 years again showed an increase of anagen rates within 3 
months of treatment (unpublished data), we performed a double blind placebo 
controlled study with the aim to verify efficacy of CYP complex in women aged 60 
years or more. 
 
While both placebo and active compound showed significant improvement of mean 
anagen rates, between the two groups these changes were not significant. Herein we 
demonstrate that the impact of seasonality of hair growth and shedding and 
heterogeneity of patient inclusion in relation to the season were enough to distort 
clinical efficacy results. 
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3. Patients and Methods 
 
Patients and Treatment 
The trial was carried out as a single centre, randomized, double-blind, controlled, 
parallel group study to compare the efficacy of a CYP-complex based active 
compound with placebo in treating telogen effluvium in otherwise healthy women 
over a treatment duration of 6 months. Women aged 60 years or more were recruited 
through advertisement in the lay press.  
 
Inclusion criteria were a history of increased hair loss, with or without clinical findings 
of female pattern hair loss (FPHL) Ludwig type I or II, and a centroparietal telogen 
hair rate > 20%, determined by the TrichoScan.  
 
Exclusion criteria included: symptomatic diffuse alopecia (e.g. resulting from iron 
deficiency or thyroid gland disorder); FPHL Ludwig type III; androgenic alopecia with 
or without signs of virilization related to a history of polycystic ovaries, late onset 
adrenogenital syndrome, or tumours of the ovaries, adrenals or pituitary gland; 
systemic autoimmune diseases; wasting diseases (AIDS, malignant disease); 
alopecia areata; inflammatory scarring or other scarring alopecias; other 
inflammatory conditions affecting the scalp (seborrhoeic dermatitis, psoriasis, contact 
dermatitis); any treatment for hair loss or participation in another clinical trial within 3 
months prior to entering the study; use of drugs that may cause hair loss 
(anticoagulants, lipid lowering drugs, retinoids, antiepileptics, beta-blocking agents, 
ACE inhibitors, antithyroid drugs, androgens, progestagens with partial androgenic 
effect, aromatase inhibitors, cytokines, cytotoxic drugs) within 3 months prior to 
entering the study; use of sulfonamide-containing drugs (interaction with p-
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aminobenzoic acid or PABA); initiation or termination of hormone replacement 
therapy or hormonal contraception within 6 months prior to entering the study; any 
type of hormone replacement therapy or oral contraception containing a progestagen 
with androgenic effect (norethisterone, norgestrel, levonorgestrel, lynestrenol, 
tibolone); pregnancy or lactation; known hypersensitivity to lactose (placebo) or any 
component of the active compound. 
 
The study was approved by the local Ethics Committee. If the patient was suitable for 
the study and had given her written informed consent, she was randomized into one 
of the two treatment arms and supplied with the active compound or placebo.  
 
The composition of the active compound was as follows: 1 capsule active compound: 
L-cystine 20 mg, keratin 20 mg, medicinal yeast 100 mg, calcium pantothenate 60 
mg, thiamine nitrate 60 mg, and PABA 20 mg. 1 capsule placebo: no active 
ingredient, lactose, microcrystalline cellulose, and magnesium stearate. The dosage 
was 1 capsule three times a day with meals, for the duration of the study (6 months). 
 
 Methods 
The diagnosis of telogen effluvium was based on an increase of the telogen hair rate 
> 20% in the centroparietal scalp area determined by the TrichoScan, and careful 
exclusion of other causes of hair loss. This included an in-depth history and clinical 
examination related to the begin and duration of hair loss, as well as its pattern. A 
careful personal history of diet, illness, operations, medications, including hormones. 
The following laboratory screening tests were performed (normal ranges): CRP (< 5 
mg/l), ferritin (> 10 g/l), basal TSH (0.27-4.20 mU/l).  
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To determine the telogen hair rate for inclusion, and the anagen hair rate throughout 
the study, an area of 1.8 cm2 was defined in the centroparietal scalp using a stencil 
template (diameter 16 mm). In that test zone the hair was clipped (Hairliner, Wella 
Germany). All clipped areas were marked with a central, single red tattoo. The tattoo 
was visible throughout the study. Gray or fair hairs have only limited contrast in 
comparison to the scalp. Therefore, the clipped hairs within the target area were 
dyed with a commercially available solution (RefectoCil®, Gschwentner, Vienna, 
Austria). Thereafter, the colored area was cleansed with an alcoholic solution 
(Kodan® Spray, Schülke & Mayr, Vienna, Austria) and digital images were obtained 
at 20-fold (analyzed area: 0.62 cm2) magnification by means of a digital ELM system 
(Fotofinder DERMA, Teachscreen Software, Bad Birnbach, Germany) while the area 
was still wet. This digital camera is equipped with a rigid contact lens which ensures 
that the images are always taken at the same distance from the scalp. Images were 
taken at day zero immediately after clipping, and three days after clipping, and three 
and six months after the initial visit, respectively. For measurement of anagen hair 
rated a commercially available software (TrichoScan) developed specially for this 
purpose was used (DatInf, Tübingen) [1]. 
 
The measures of outcome were the anagen hair rate at baseline, after 3 and 6 
months of treatment. 
 
Randomization of patients was done with RANCODE, version 3.6, including 45 
patients. Treatment 1 was verum, treatment 2 placebo at a ratio of 1:1, no 
stratification. 
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Statistics 
Patients receiving active compound were compared with placebo at baseline (T = 0), 
3 months (T = 3) and 6 months (T = 6). Repeated measures ANOVA with 
Greenhouse – Geisser correction was performed to analyze the anagen rates (AR) in 
% over time. Changes of AR over 6 months were compared between the two groups 
using the unpaired t-test. 
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4. Results 
 
A total of 45 patients were enrolled. 36 completed the study: 15 in the active 
compound group, 21 in the placebo group. Nine patients withdrew from the trial due 
to: intercurrent unrelated illness (3, 2 on active compound and 1 on placebo), use of 
drugs that may cause hair loss (3, all on active compound), gastrointestinal upset (2, 
1 on active compound, 1 on placebo), and initiation of other treatment for hair loss 
(other dietary supplement, 1 on placebo).  
 
The age range of the women who completed the study was 60 - 82 years (mean: 68 
years), in the active compound group 60 – 78 (mean: 68 years), in the placebo group 
60 – 82 years (mean: 68 years). 
 
The results of the anagen hair rates (in %) at baseline, 3, and 6 months are 
presented in terms of descriptive statistics in Table 1 and showed graphically in 
Figure 1.  There was an overall significant increase AR % over time (p < 0.001), with 
no significant interaction between time and treatment (p = 0.19). The overall 
difference between the two groups was not significant (p = 0.97). The changes of AR 
in % between the two groups over 6 months were not significant (p = 0.12). 
 
The active compound was generally well tolerated: 1 patient reported gastrointestinal 
symptoms. 
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Table 1. Results of anagen hair rates (%) 
 
 
Active compound Placebo 
 N 
 
AR % 
Min. 
AR % 
Max. 
AR % 
Mean Std.D. N 
AR % 
Min. 
AR % 
Max. 
AR % 
Mean Std. D. 
 
T= 0 months 15 62 79 73.3 6.1 21 58 79 74.2 6.5 
 
T= 3 months 15 62 86 75.9 6.6 21 52 93 76.9 9.0 
 
T= 6 months 15 63 88 79.1 6.6 21 44 90 77.0 9.9 
 
 
Figure 1. Improvement of anagen rates after treatment 
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5. Discussion 
 
The hair follicle is subject to constant turnover in the course of perpetual cycles 
through phases of proliferation during anagen, involution during catagen and resting 
during telogen, with regeneration in the successive hair cycle. In telogen, the hair 
shaft matures into a club hair, which is held tightly in the bulbous base of the follicular 
epithelium, before it is eventually shed during teloptosis [6,7]. Cyclic hair growth 
activity occurs in a random mosaic pattern with each follicle possessing its own 
individual control mechanism over the evolution and triggering of the successive 
phases. Systemic factors, such as the hormonal system, cytokines and growth 
factors, as well as external factors linked to the environment, toxins, deficiencies of 
nutrients, vitamins and energy, have influence. 
 
In general, the pathological dynamics of hair loss can be related to disorders of hair 
cycling [8]. Whatever the cause, the follicle tends to behave in a similar way, with 
telogen effluvium representing the most frequent cause of hair loss [9]. 
 
Telogen effluvium results from a disruption of the hair cycle resulting in increased 
proportion and shedding of telogen hair (> 15%). Hair loss usually affects less than 
50% of scalp hair and presents with diffuse thinning of the hair, that is most 
conspicuous at the temples, and a positive hair pull test of telogen club hairs. 
 
Headington [10] proposed a classification of telogen effluvium into different functional 
types based on changes in the different phases of the hair cycle. Telogen effluvium 
may either result from synchronization phenomena of the hair cycle with an increase 
in shedding of hairs from the telogen phase of the cycle, or from shortening of the 
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duration of the anagen phase. While synchronization phenomena underlie diffuse 
telogen effluvium, shortening of the duration of anagen underlies androgenetic 
alopecia. Finally, Headington also suggested that a delayed telogen release 
underlies moulting in mammals, and possibly mild telogen effluvia in humans 
following travel from low-daylight to high-daylight conditions. In this case, hair follicles 
remain in a prolonged telogen phase rather than being shed and recycling into 
anagen. When finally teloptosis sets in, again the clinical sign of increased shedding 
of club hairs is observed. 
 
In a former study of 823 otherwise healthy women with telogen effluvium during an 
observational period of 6 years, the existence of an overall annual periodicity in the 
growth and shedding of hair was demonstrated, manifested by a maximal proportion 
of telogen hairs in July [11]. Taking a scalp hair telogen phase duration of 
approximately 100 days into account, one would expect shedding of these hairs by 
autumn. A second peak seems to exist, although less pronounced, in April. These 
findings confirmed the results of prior studies performed in smaller populations and 
male subjects [12,13]. It was pointed out that the existence of seasonal fluctuations in 
hair growth and shedding would potentially complicate the assessment of 
pharmacological effects, and therefore would have serious implications for 
investigations with hair-growth-promoting agents: depending on the stage of 
periodicity in growth and shedding of hair for a particular subject, the heterogeneity of 
included subjects may be enough to distort the clinical efficacy results and the 
perceived benefit of an investigational agent. In the active stage of seasonal telogen 
effluvium, the involved hair follicles would probably fail to respond to the therapeutic 
agent, which may cause a false-negative result. In the recovery stage, the increased 
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amounts of spontaneous hair regrowth might be interpreted falsely as a positive 
result. 
 
In the present study, both placebo and active compound showed significant 
improvement of mean anagen rates within the 6 months of treatment. Despite prior 
evidence of efficacy of CYP-based nutritional supplement over placebo [5], the 
changes of anagen rates between the two groups were not significant. 
 
This observation was explained by inhomogeneous inclusion of study patients in 
relation to seasonality of hair growth and shedding (Fig. 2 A-C): In the placebo group 
a cluster of 7 patients (versus 1 patient in the active compound group) were included, 
that profited from seasonal hair growth within the first 3 months of the study. From 3 
to 6 months the AR in % in the placebo group flattened, while in the active compound 
group the AR in % further increased and exceeded the placebo group (Fig. 1). 
 
We conclude that the impact of seasonality of hair growth and shedding must be 
taken into consideration in clinical trials with hair growth promoting agents, especially 
in studies with small numbers of patients and short study durations. Care should be 
taken to maximize homogeneous patient inclusion in relation to the season. 
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Figure 2. Inhomogeneous inclusion of study patients in relation to periodicity of hair growth 
and shedding: A. at inclusion, B. at 3 months, C. at 6 months. Ellipse highlights cluster of  
patients in the placebo group that profited from seasonal hair growth within first 3 months. 
 
 
 
 
A. 
B. 
C. 
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